A Comparison of the Efficacy of Clonazepam and Cognitive-Behavioral Group Therapy for the Treatment of Social Phobia
The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
There is a growing body of evidence that social phobia may be treated effectively by either pharmacologic or cognitive-behavioral interventions. but few studies have examined the relative benefits of these treatments. In this study, we examined the relative efficacy of pharmacotherapy with clonazepam and cognitive-behavioral group therapy (CBGT) for treating social phobia. In addition, we examined potential predictors of differential treatment response. Outpatients meeting Diagnostic and Statistical Manual of Mental Disorders (3rd ed., revised) criteria for social phobia were randomly assigned to treatment. Clinician-rated and patient-rated symptom severity was examined at baseline and after 4, 8, and 12 weeks of treatment. All clinician-rated assessments were completed by individuals blind to treatment condition. Patients in both conditions improved significantly, and differences between treatment conditions were absent, except for greater improvement on clonazepam on several measures at the 12-week assessment. Symptom severity was negatively associated with treatment success for both methods of treatment, and additional predictors-sex, comorbidity with other anxiety or mood disorders, fear of anxiety symptoms, and dysfunctional attitudes-failed to predict treatment outcome above and beyond severity measures. In summary, we found that patients randomized to clinical care with clonazepam or CBGT were equally likely to respond to acute treatment, and pretreatment measures of symptom severity provided no guidance for the selection of one treatment over another.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, additional studies all show a continuing anxiolytic effect, at least for panic disorder [69–72], generalized anxiety disorder [73], and social phobia [74–76].”
From Mechanisms Underlying Tolerance after Long-Term Benzodiazepine Use: A Future for Subtype-Selective Receptor Modulators? (2012) · cites this paper as [76]
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Kessler, R. C. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950010008002 · Cited by 12,370 · cited 1×
“…Social phobia; Cognitive-behavioral therapy; Clonazepam; Social anxiety disorder; Benzodiazepine The lifetime prevalence of social phobia is approximately 13%, making it the third most common psychiatric disorder in the community after major depression and alcohol dependence (Kessler et al., 1994).”
BackgroundThe assessment of anxiety states by rating
HAMILTON, M. (1959) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1959.tb00467.x · Cited by 11,455 · cited 2×
“All clinician-rated assessments were completed by individuals blind to treatment condition and included the Clinical Global Impression Scale for severity (CGI; Guy, 1976) with scores ranging from 1 (“not ill”) to 7 (“among most severely ill”), the Liebowitz Social Anxiety Scale (LSAS; Liebowitz, 1987), and the Hamilto…”
Method(1976) · Medical Entomology and Zoology · Cited by 8,899
Diagnostic and Statistical Manual of Mental Disorders (3rd ed. rev.)
Drake, M. (1988) · The American Journal of Occupational Therapy · doi:10.5014/ajot.42.10.683b · Cited by 5,240
Mattick, R. P., & Clarke, J. C. (1998) · Behaviour Research and Therapy · doi:10.1016/s0005-7967(97)10031-6 · Cited by 3,367
Liebowitz, M. R. (2015) · Modern Trends in Pharmacopsychiatry · doi:10.1159/000414022 · Cited by 2,266
A brief version of the Fear of Negative Evaluation Scale
Leary, M. R. (1983) · Personality and Social Psychology Bulletin · doi:10.1177/0146167283093007 · Cited by 2,178 · cited 1×
“1989), the brief version of the Fear of Negative Evaluation Scale (FNE; Leary, 1983), and the Rathus Assertiveness Schedule (RAS; Rathus, 1973).”
BackgroundDesigning Experiments and Analysing Data: A Model Comparison Perspective.
Freeman, G. H., Maxwell, S. E., & Delaney, H. D. (1991) · Biometrics · doi:10.2307/2532173 · Cited by 1,229
Schneier (1992) · doi:10.1001/archpsyc.1992.01820040034004 · Cited by 1,142 · cited 1×
“The issue of treatment preference is clouded by the exceptionally low rates at which individuals with social phobia seek treatment (Schneier et al., 1992), and in our sample we observed an average 24-year interval between the onset of the social phobia and entry into our treatment trial.”
Background
Research works printed but not linked: 2
- Liebowitz, 1999, Cognitive-behavioral group theory versus phenelzine in social phobia, Depression and Anxiety, 10, 89, 10.1002/(sici)1520-6394(1999)10:3<89::aid-da1>3.0.co;2-5 · doi:10.1002/(sici)1520-6394(1999)10:3<89::aid-da1>3.0.co;2-5
- Weissman, 1979, The Dysfunctional Attitude Scale, Dissertation Abstracts International, 40, 1389
Cited by
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
“pam (Level 1) [470][385,471], alprazolam [386], and bro-”
Baldwin, D. S., Anderson, I. M., Nutt, D. J., Bandelow, B., Bond, A., Davidson, J. R. T., den Boer, J. A., Fineberg, N. A., Knapp, M., Scott, J., et al. (2005) · Journal of Psychopharmacology · doi:10.1177/0269881105059253 · Cited by 617
A Meta-Analytic Review of Adult Cognitive-Behavioral Treatment Outcome Across the Anxiety Disorders
Norton, P. J., & Price, E. C. (2007) · Journal of Nervous & Mental Disease · doi:10.1097/01.nmd.0000253843.70149.9a · Cited by 612
Augmentation of Exposure Therapy With D-Cycloserine for Social Anxiety Disorder
Hofmann, S. G., Meuret, A. E., Smits, J. A. J., Simon, N. M., Pollack, M. H., Eisenmenger, K., Shiekh, M., & Otto, M. W. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.3.298 · Cited by 560
“These controlled effect sizes indicate an advantage of exposure therapyandDCSover standardexposure-based treatment that is already associated with strong treatment effect as delivered in longer treatment protocols.(13,16,17) Moreover, the results indicate that combining DCS with exposure therapy that is focused on a c…”
BackgroundSelf-citationPrediction as a Humanitarian and Pragmatic Contribution from Human Cognitive Neuroscience
Gabrieli, J. D. E., Ghosh, S. S., & Whitfield-Gabrieli, S. (2015) · Neuron · doi:10.1016/j.neuron.2014.10.047 · Cited by 535
Metadata
- Authors
- Otto, M. W., Pollack, M. H., Gould, R. A., Worthington, J. J., McArdle, E. T., Rosenbaum, J. F., & Heimberg, R. G.
- Affiliations
- Harvard University (US)
- Temple University (US)
- Corresponding author
- Otto, Michael W
- Venue
- Journal of Anxiety Disorders
- Publisher
- Elsevier BV
- Published
- 2000-07
- Volume
- 14
- Issue
- 4
- Pages
- 345-358
- ISSN
- 0887-6185 (ISSN-L)
- OpenAlex
- W1976832836
- Cited by
- 175
- References
- 45
- Citations by year
- 2026: 3 · 2025: 4 · 2024: 6 · 2023: 2 · 2022: 1 · 2021: 4 · 2020: 4 · 2019: 3 · 2018: 3 · 2017: 3 · 2016: 4 · 2015: 6 · 2014: 11 · 2013: 9 · 2012: 11
- FWCI
- 14.64
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- Journal of Anxiety Disorders (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Social Sciences › Psychology › Clinical Psychology › Psychological Treatments and Assessments
- Social Sciences › Psychology › Clinical Psychology › Psychotherapy Techniques and Applications
- Keywords
- social anxiety disorder, clonazepam, group cognitive behavioral therapy, pharmacotherapy, treatment outcome comparison, predictors of treatment response, symptom severity, anxiety disorders, comorbidities, dysfunctional attitudes, sex differences
- MeSH terms
- Adult, Analysis of Variance, Clonazepam, Female, Humans, Male, Phobic Disorders, Severity of Illness Index, Cognitive Behavioral Therapy, GABA Modulators
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Comparison of the Efficacy of Clonazepam and Cognitive-Behavioral Group Therapy for the Treatment of Social Phobia. https://app.cochat.ai/papers/10.1016/s0887-6185(00)00027-x
- The paper
- Otto, M. W., Pollack, M. H., Gould, R. A., Worthington, J. J., McArdle, E. T., Rosenbaum, J. F., & Heimberg, R. G. (2000). A Comparison of the Efficacy of Clonazepam and Cognitive-Behavioral Group Therapy for the Treatment of Social Phobia. Journal of Anxiety Disorders. https://doi.org/10.1016/s0887-6185(00)00027-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.